These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4282 related articles for article (PubMed ID: 15829967)

  • 21. Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
    Qu J; Sun W; Zhong J; Lv H; Zhu M; Xu J; Jin N; Xie Z; Tan M; Lin SH; Geng M; Ding J; Huang M
    J Cell Biol; 2017 Feb; 216(2):409-424. PubMed ID: 28122957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
    Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
    J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
    Leung M; Rosen D; Fields S; Cesano A; Budman DR
    Mol Med; 2011; 17(7-8):854-62. PubMed ID: 21424107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.
    Helleday T
    Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular pathways: targeting PARP in cancer treatment.
    Do K; Chen AP
    Clin Cancer Res; 2013 Mar; 19(5):977-84. PubMed ID: 23269547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA repair deficiency as a therapeutic target in cancer.
    Martin SA; Lord CJ; Ashworth A
    Curr Opin Genet Dev; 2008 Feb; 18(1):80-6. PubMed ID: 18343102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
    Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
    J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
    Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarker-Guided Development of DNA Repair Inhibitors.
    Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
    Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PARP inhibitors in breast cancer: BRCA and beyond.
    Rios J; Puhalla S
    Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
    Croset A; Cordelières FP; Berthault N; Buhler C; Sun JS; Quanz M; Dutreix M
    Nucleic Acids Res; 2013 Aug; 41(15):7344-55. PubMed ID: 23761435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
    Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
    Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical development of inhibitors of poly(ADP-ribose) polymerase.
    Calvert H; Azzariti A
    Ann Oncol; 2011 Jan; 22 Suppl 1():i53-9. PubMed ID: 21285153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
    Lord CJ; Ashworth A
    Nat Med; 2013 Nov; 19(11):1381-8. PubMed ID: 24202391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 215.